文献速递浆细胞疾病

POEMS综合征:2021年诊断、风险分层与管理更新

POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management.
PubMed 文献 · Am J Hematol · 2021-05-31

POEMS综合征是源于浆细胞肿瘤的副肿瘤综合征,主要诊断标准包括多神经根神经病、克隆性浆细胞病、硬化性骨病变、血管内皮生长因子升高及Castleman病。诊断需满足三项主要标准(必须含多神经根神经病和克隆性浆细胞病)及至少一项次要标准。风险分层基于临床表型,高危因素包括低白蛋白、年龄、胸腔积液、肺动脉高压和eGFR降低。治疗上,孤立性浆细胞瘤首选放疗,弥漫性病变或放疗后进展者需全身治疗,烷化剂为主,来那度胺有前景但需注意神经毒性。

要点

  • 诊断需三项主要标准(必含多神经根神经病和克隆性浆细胞病)加至少一项次要标准。
  • 高危因素包括低白蛋白、年龄、胸腔积液、肺动脉高压和eGFR降低。
  • 孤立性浆细胞瘤首选放疗,弥漫性病变或放疗后3-6个月进展者需全身治疗。

核心结论

  • POEMS综合征的诊断基于主要和次要标准的组合,风险分层依赖临床表型而非分子标志物。
  • 治疗应根据疾病范围选择放疗或全身治疗,烷化剂是全身治疗的主要药物,来那度胺有应用前景。

研究设计与样本

  • 本文为2021年更新的综述,总结了POEMS综合征的诊断标准、风险分层和治疗管理。

主要发现

  • 主要诊断标准包括多神经根神经病、克隆性浆细胞病、硬化性骨病变、血管内皮生长因子升高和Castleman病。
  • 诊断需满足三项主要标准(必须包括多神经根神经病和克隆性浆细胞病)和至少一项次要标准。
  • 风险因素包括低血清白蛋白、年龄、胸腔积液、肺动脉高压和eGFR降低。

关键数值与推荐

  • 诊断标准:三项主要标准(必含多神经根神经病和克隆性浆细胞病)加至少一项次要标准。
  • 风险因素:低血清白蛋白、年龄、胸腔积液、肺动脉高压、eGFR降低。
  • 治疗推荐:孤立性浆细胞瘤首选放疗;弥漫性硬化病变或骨髓广泛受累或放疗后3-6个月进展者需全身治疗;烷化剂为主要药物,可低剂量常规或高剂量联合干细胞移植;来那度胺有效且毒性可控;沙利度胺和硼替佐米有效但需权衡周围神经病风险。

临床怎么用

  • 临床怀疑POEMS综合征时应检查主要和次要标准以明确诊断。
  • 根据风险因素进行分层,并针对孤立性浆细胞瘤选择放疗,弥漫性病变选择全身治疗。
  • 全身治疗首选烷化剂,可考虑来那度胺,使用沙利度胺或硼替佐米时需监测周围神经病。

局限性

  • 由于发病机制未完全阐明,风险分层仅限于临床表型,缺乏分子标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: POEMS syndrome is a paraneoplastic syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyradiculoneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease. Minor features include organomegaly, endocrinopathy, characteristic skin changes, papilledema, extravascular volume overload, and thrombocytosis. DIAGNOSIS: The diagnosis of POEMS syndrome is made with three of the major criteria, two of which must include polyradiculoneuropathy and clonal plasma cell disorder, and at least one of the minor criteria. RISK STRATIFICATION: Because the pathogenesis of the syndrome is not well understood, risk stratification is limited to clinical phenotype rather than specific molecular markers. Risk factors include low serum albumin, age, pleural effusion, pulmonary hypertension, and reduced eGFR. RISK-ADAPTED THERAPY: For those patients with a dominant plasmacytoma, first line therapy is irradiation. Patients with diffuse sclerotic lesions or disseminated bone marrow involvement and for those who have progression of their disease 3-6 months after completing radiation therapy should receive systemic therapy. Corticosteroids are temporizing, but alkylators are the mainstay of treatment, either in the form of low dose conventional therapy or high dose with stem cell transplantation. Lenalidomide shows promise with manageable toxicity. Thalidomide and bortezomib also have activity, but their benefit needs to be weighed against their risk of exacerbating the peripheral neuropathy. Prompt recognition and institution of both supportive care measures and therapy directed against the plasma cell result in the best outcomes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Dispenzieri A. POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2021. PMID: 34000085. doi:10.1002/ajh.26240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。